Navigation Links
Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Date:8/4/2008

PALO ALTO, Calif., Aug. 4 /PRNewswire/ -- Anacor Pharmaceuticals announced today that it has appointed Kurt Jarnagin, Ph.D., as its Vice President of Biological Research.

"We are pleased to welcome Kurt to the company," said Jacob Plattner, Ph.D., Senior Vice President of Research at Anacor Pharmaceuticals. "Kurt is a noted expert in the field of small molecule drugs involved in inflammation and his expertise will enrich our team as we continue to expand our pipeline fed by our boron chemistry platform."

Previously, Dr. Jarnagin was with Iconix Pharmaceuticals, Inc., serving as Vice President of Biology and Chemogenomics and Vice President of New Technology and Translational Medicine from 1998 to 2007. Dr. Jarnagin also held research leadership roles at Roche Pharmaceuticals (Palo Alto) from 1994 to 1998 and at Syntex Research, a specialty pharmaceutical company acquired by Roche, from 1986 to 1994.

At Iconix he directed the development of the DrugMatrix and ToxFX products -- tools and decision-making resources that aid scientists in the selection and prioritization of novel drugs. At Roche and Syntex he focused on drug discovery, targeting receptors and enzymes involved in inflammation, arthritis and asthma. Dr. Jarnagin was awarded the Fry-E. Werele International Kinin Chemistry Prize for work in the bradykinin field. He is the author of numerous peer-reviewed scientific papers and has several granted patents.

Dr. Jarnagin carried out highly cited studies of the insulin receptor at the Hormone Research Institute of the University of California, San Francisco. He received his Ph.D. in Biochemistry from the University of Wisconsin, Madison, and holds a B.S. in Biochemistry from North Carolina State University in Raleigh.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to Schering-Plough under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. Anacor also has a research and development collaboration with GlaxoSmithKline for the discovery, development, manufacture and worldwide commercialization of novel systemic therapeutics for viral and bacterial diseases utilizing Anacor's boron-based chemistry. For more information visit http://www.anacor.com.


'/>"/>
SOURCE Anacor Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory Candidates, AN2728 and AN2898, at the International Investigative Dermatology 2008 Conference
2. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
3. Anacor Files Registration Statement for Initial Public Offering
4. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
5. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
6. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
7. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
8. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
9. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
10. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
11. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... DIEGO , June 27, 2016  Sequenom, Inc. ... committed to enabling healthier lives through the development of ... Court of the United States ... courts that the claims of Sequenom,s U.S. Patent No. ... patent eligibility criteria established by the Supreme Court,s Mayo ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):